Skip to main content
OpenTrials
Completed

NCT Number: NCT01482455

Fat and Transcapillary Insulin Transport

There is a current debate whether impaired insulin-mediated microvascular perfusion limits the delivery of hormones and nutrients to muscle and whether short term FFA elevation affects transcapillary transport of insulin and glucose thereby representing a rate-controlling step for insulin-stimulated muscular glucose disposal in humans.

To address these questions, the investigators determined the changes of interstitial glucose and insulin in skeletal muscle of healthy volunteers during intravenous administration of triglycerides or glycerol under physiologic and supraphysiologic hyperinsulinemic conditions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Medical University Vienna

Vienna, 1090, Austria

About this study

Increased lipid availability reduces insulin-stimulated glucose disposal in skeletal muscle, which is generally explained by lipid induced inhibition of myocellular insulin signalling, It remains unclear whether lipids also impair transcapillary transport of insulin and glucose which could thereby become rate-controlling for glucose disposal Increased accumulation and availability of lipids cause impaired skeletal muscle insulin sensitivity. It is yet unclear if transcapillary transport of insulin and glucose is impaired by acute elevation of free fatty acids and represents a rate-limiting step during the development of short-term lipid-induced insulin resistance. We determined the changes of interstitial glucose and insulin in skeletal muscle of healthy volunteers during intravenous administration of triglycerides and heparin or glycerol under physiologic and supraphysiologic hyperinsulinemic conditions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The volunteers have to be older than 19 years,
  • nonobese (body mass index, BMI less than 27 kg/m2),
  • normolipidemic (fasting serum concentration of triglycerides < 140 mg/dL and
  • total cholesterol < 200 mg/dL) and
  • non-smokers.

Exclusion criteria

  • The following exclusion criteria will be applied:
  • any medication within two weeks prior to the start of study,
  • regular alcohol consumption > 40 g/d,
  • acute inflammatory disease defined by serum C-reactive protein > 1 mg/dL,
  • abnormalities in the screening visit or in laboratory tests considered as clinically relevant,
  • family history of diabetes mellitus or dyslipidemia,
  • glucose intolerance,
  • allergy or hypersensitivity against study medication,
  • blood clotting disorders.

Treatment and study plan

Elevation of FFA during OGTT

Other

0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin "Immuno"®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1

Elevation of FFA during Clamp

Other

0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin "Immuno"®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1.

Primary outcomes

  1. Blood flow

    Time frame: between the start of the lipid/glycerol infusion until the end of the study (360 min)

    Regional blood flow. Muscular blood flow will be measured by the laser Doppler flow technique (LDF, Moor Instruments, Devon, UK) as described previously

Secondary outcomes

  1. Interstitial insulin concentration

    Time frame: between the start of the lipid/glycerol infusion until the end of the study (360 min)

    Interstitial insulin concentration in skeletal muscle is measured via microdialysis based on sampling of analytes from the interstitial space fluid by means of a dialysis membrane at the tip of a microdialysis probe.

Sponsors and collaborators

Lead sponsor

German Diabetes Center

Other

Collaborators

  • Medical University of Vienna

Registry information

Official study title

Lipid-induced Insulin Resistance is Not Mediated by Impaired Transcapillary Transport of Insulin and Glucose in Humans

Acronym: FATRAIN

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Nov 30, 2011
Registry last updated
Jun 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.